Helen Mooney

Apr 30, 2024 | healthaffairs.org | Daniel A. Ollendorf |Leah Z. Rand |Helen Mooney |Marie Phillips |Anirban Basu

From the time that the Centers for Medicare and Medicaid Services (CMS) first provided public guidance on its intended approach for negotiating the price of the first 10 drugs selected for Medicare’s drug price negotiation program, there has been much speculation on the gaps in the available guidance. For example, it’s all well and good to say that a number of factors will be used in negotiation, but how are those factors weighted and used to determine a numeric output, the price?